New drug combo aims to reignite immune attack on tough childhood cancer

NCT ID NCT07085338

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding an experimental immune-boosting drug (N-803) to standard chemoimmunotherapy can help children and young adults whose neuroblastoma has returned or not responded to treatment. About 54 participants will receive the combination to see if it is safe and works better than the current approach. The goal is to shrink tumors and improve survival without causing severe side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Colorado

    NOT_YET_RECRUITING

    Colorado Springs, Colorado, 80902, United States

  • Motts Childrens Hospital

    NOT_YET_RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact

    Contact

  • St. Jude Children's Research Hospital

    RECRUITING

    Memphis, Tennessee, 38105, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of California San Francisco

    NOT_YET_RECRUITING

    San Francisco, California, 94158, United States

    Contact

    Contact